Literature DB >> 22266871

Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.

K Kudo1, E Gavin, S Das, L Amable, L A Shevde, E Reed.   

Abstract

The transcription of ERCC1 and other nucleotide excision repair (NER) genes is strongly influenced by c-jun. C-jun is transcriptionally regulated by Gli proteins of the Hedgehog pathway. We therefore studied the possible relationships between Gli1, c-jun, and the upregulation of ERCC1, XPD and XRCC1 in cisplatin-resistant human ovarian cancer cells. We studied the paired human ovarian cancer cell lines A2780 and A2780-CP70. We used a shRNA construct that specifically degrades Gli1 message. Genes we assessed for mRNA and/or protein levels included: c-jun, ERCC1, XPD, XRCC1, Gli1, Gli2, SHH, IHH, GAPDH and α-tubulin. Platinum-DNA adduct repair was assessed by atomic absorbance spectrometry with Zeeman background correction. Use of the anti-Gli1 shRNA in cisplatin-resistant cells resulted in a block of the cell's ability to upregulate genes in response to cisplatin treatment, including: c-jun, ERCC1, XPD and XRCC1. This block in upregulation of c-jun was concurrent with a change in the phosphorylation pattern of the c-jun protein, shifting that pattern from a Ser63/73 dominant pattern, to a Thr91/93 dominant pattern. A2780-CP70 cells were treated at their cisplatin IC50, and DNA repair was assessed after pretreatment with anti-Gli1 shRNA or scrambled shRNA control. Control cells repaired 78% of platinum-DNA adducts at 12 h, compared with 33% repair in cells pretreated with anti-Gli1 shRNA resulting in a 2.4-fold difference. Pretreatment of A2780-CP70 cells with anti-Gli1 shRNA resulted in supra-additive cell killing with cisplatin; shifting the cisplatin IC50 (half maximal inhibitory concentration) from 30 μM to 5 μM. Pretreatment of these cells with cyclopamine did not shift the cisplatin IC50. We conclude that the transcriptional protein Gli1 is important in the upregulation of these three DNA repair genes in human ovarian cancer cells, and that Gli1 strongly influences platinum-DNA adduct repair, and cellular sensitivity to cisplatin. This Gli1 role has c-jun as an intermediate in the pathway. In all, inhibition of Gli1 by a specific shRNA inhibits the upregulation of c-jun Ser63/73, and also inhibits the upregulation of three genes essential to NER (ERCC1, XPD) and base excision repair (XRCC1).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266871     DOI: 10.1038/onc.2011.610

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.

Authors:  Kai Li; Wusheng Li
Journal:  Mol Cell Biochem       Date:  2012-09-16       Impact factor: 3.396

2.  Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors.

Authors:  Kaushlendra Tripathi; Chinnadurai Mani; Reagan Barnett; Sriram Nalluri; Lavanya Bachaboina; Rodney P Rocconi; Mohammed Athar; Laurie B Owen; Komaraiah Palle
Journal:  J Biol Chem       Date:  2014-09-24       Impact factor: 5.157

3.  Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.

Authors:  Rui-Lan Huang; Fei Gu; Nameer B Kirma; Jianhua Ruan; Chun-Liang Chen; Hui-Chen Wang; Yu-Ping Liao; Cheng-Chang Chang; Mu-Hsien Yu; Jay M Pilrose; Ian M Thompson; Hsuan-Cheng Huang; Tim Hui-Ming Huang; Hung-Cheng Lai; Kenneth P Nephew
Journal:  Epigenetics       Date:  2013-05-10       Impact factor: 4.528

4.  Transcriptome of the inner circular smooth muscle of the developing mouse intestine: Evidence for regulation of visceral smooth muscle genes by the hedgehog target gene, cJun.

Authors:  Katherine Gurdziel; Kyle R Vogt; Katherine D Walton; Gary K Schneider; Deborah L Gumucio
Journal:  Dev Dyn       Date:  2016-03-17       Impact factor: 3.780

5.  Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.

Authors:  Chun-Liang Tung; Yi-Jun Jian; Jyh-Cheng Chen; Tai-Jing Wang; Wen-Ching Chen; Hao-Yu Zheng; Po-Yuan Chang; Kai-Sheng Liao; Yun-Wei Lin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-03-30       Impact factor: 3.000

6.  Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.

Authors:  Shrey Modi; Devika Kir; Bhuwan Giri; Kaustav Majumder; Nivedita Arora; Vikas Dudeja; Sulagna Banerjee; Ashok K Saluja
Journal:  J Gastrointest Surg       Date:  2015-10-26       Impact factor: 3.452

7.  GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.

Authors:  Krishan Kumar; Sania S Raza; Lawrence M Knab; Christina R Chow; Benjamin Kwok; David J Bentrem; Relja Popovic; Kazumi Ebine; Jonathan D Licht; Hidayatullah G Munshi
Journal:  Sci Rep       Date:  2015-03-25       Impact factor: 4.379

8.  JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.

Authors:  W Xu; Q Chen; Q Wang; Y Sun; S Wang; A Li; S Xu; O D Røe; M Wang; R Zhang; L Yang; J Zhou
Journal:  Cell Death Dis       Date:  2014-12-04       Impact factor: 8.469

9.  The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

Authors:  Yong-Ping Liu; Yang Ling; Qiu-Feng Qi; Ya-Ping Zhang; Chang-Song Zhang; Chang-Tai Zhu; Mei-Hua Wang; Yao-Dong Pan
Journal:  Oncol Lett       Date:  2012-12-28       Impact factor: 2.967

10.  Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.

Authors:  Alessandra Ciucci; Ilaria De Stefano; Valerio Gaetano Vellone; Lucia Lisi; Carolina Bottoni; Giovanni Scambia; Gian Franco Zannoni; Daniela Gallo
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.